ArticleFrontiers in bioengineering and biotechnology2026
3D-bioprinted microenvironments shape the growth and IgG1 monoclonal antibody production of CHO DG44 cells.
Article in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Three-dimensional (3D) bioprinting offers new possibilities to recreate in vivo-like microenvironments for mammalian cells, with potential applications in therapeutic bioproduction. Methods: In this study, we evaluate the growth, central carbon metabolism, and IgG1 monoclonal antibody (mAb) bioproduction of Chinese hamster ovary (CHO) DG44 cells embedded in 3D-bioprinted hydrogel constructs under different cultivation strategies: batch, semicontinuous, and both modes preceded by a 3D amplification step in an amplification medium. Results and Discussion: Across all 3D conditions, CHO DG44 cells exhibited markedly reduced and limited growth over 14 days, most likely due to restricted nutrient diffusion and limited available space imposed by the intrinsic porosity of the bioink. Glucose was not depleted under any condition. In semicontinuous cultures, glucose consumption and lactate production remained approximately constant over the full culture duration, whereas both processes stopped midrun in batch cultures. The relatively low overall glucose consumption indicates that higher cell-to-medium ratios could be implemented to improve nutrient utilisation. mAb production closely followed lactate metabolism, with sustained production in semicontinuous cultures and an early plateau in batch mode, resulting in 2- to 3-fold lower final mAb amounts in batch compared with semicontinuous cultures. Introducing a 3D amplification phase more than doubled cumulative mAb production after 14 days. Overall, low growth, low titres, low space-time yields, and residual nutrients in the supernatant show that the current 3D-bioprinting strategy is not yet optimal for mAb manufacturing. However, despite this apparent weakness of the 3D-bioprinted environment for production, the 3D specific productivity of 3D-amplified semicontinuous conditions was found to be higher than the global suspension specific productivity. Consequently, our data suggest that increasing the cell-to- medium ratio and reducing the construct size to mitigate diffusion limitations enhance cell-specific productivity and process efficiency in 3D-bioprinted CHO- based bioproduction systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.